title: Effect of diabetes mellitus on the outcome of patients with resected non-small cell lung carcinoma.
abstract: BACKGROUND
  Both diabetes mellitus (DM) and non-small cell lung carcinoma (NSCLC) are age-related diseases and therefore occur simultaneously. DM and, in particular, diabetic nephropathy are associated with an increased modification of the extracellular tissue matrix with advanced glycation end-products (AGEs).
  
  
  OBJECTIVE
  As AGE-modified matrix impairs the invasive migration of lung carcinoma cells, our study aimed at the effect of DM on the NSCLC-related outcome.
  
  
  METHODS
  In a retrospective clinical study, we analyzed the time-dependent survival of NSCLC patients with DM compared to patients without DM, who had been treated for cancer by resection surgery. The age-matched study population (51-80 years) included 55 DM patients and 111 non-DM patients.
  
  
  RESULTS
  Comparative analyses between DM and non-DM patients did not find significant differences for NSCLC histology, tumor stage and stay in the hospital. Analyses of the mid-term (20-month) survival showed that the DM group had a significantly higher proportion of NSCLC patients being alive 20 months after tumor resection than the non-DM group (76 vs. 59%, p = 0.048). The DM-related increase in the mid-term survival rate was particularly observed for patients without lymph node metastasis (88%) and those patients also suffering from nephropathy (90%). In contrast to the mid-term survival, DM had no effect on the long-term (60-month) survival of NSCLC patients (35 vs. 32% in the non-DM group).
  
  
  CONCLUSIONS
  Our study indicates that DM-associated changes mediate beneficial effects in terms of NSCLC progression, in which AGE modifications might play a critical role.
authors.affiliation: Department of Cardio-Thoracic Surgery, University Hospital Halle (Saale), Martin Luther University Halle-Wittenberg, Halle (Saale), Germany. babett.bartling@medizin.uni-halle.de
authors.forename: Babett
authors.initials: B
authors.lastname: Bartling
authors.forename: Andreas
authors.initials: A
authors.lastname: Simm
authors.forename: Antonia
authors.initials: A
authors.lastname: Sohst
authors.forename: Rolf-Edgar
authors.initials: RE
authors.lastname: Silber
authors.forename: Hans-Stefan
authors.initials: HS
authors.lastname: Hofmann
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002289:Carcinoma, Non-Small-Cell Lung / Q000150:complications* / Q000401:mortality / Q000601:surgery*; D048909:Diabetes Complications / Q000378:metabolism / Q000401:mortality / Q000601:surgery*; D003928:Diabetic Nephropathies / Q000150:complications / Q000401:mortality / Q000601:surgery; D005260:Female; D005858:Germany / Q000453:epidemiology; D017127:Glycation End Products, Advanced / Q000378:metabolism; D006801:Humans; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000150:complications* / Q000401:mortality / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D017127:Glycation End Products, Advanced